Press release Biocartis Group NV: Disclosure of a transparency notification
04 Februar 2022 - 7:00AM
Press release Biocartis Group NV: Disclosure of a transparency
notification
PRESS RELEASE: REGULATED INFORMATION
4
February 2022, 07:00 CET
Disclosure of a transparency
notification
Mechelen, Belgium,
4 February 2022
– Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative
molecular diagnostics company (Euronext Brussels: BCART), announces
today, in accordance with Article 14, paragraph 1 of the
Belgian Act of 2 May 2007 on the disclosure of major shareholdings
in issuers whose shares are admitted to trading on a regulated
market (the ‘Belgian Transparency Act’), that it received a
transparency notification dated 2 February 2022 (the
‘Notification’) indicating that on that date, the aggregate number
of voting rights and equivalent financial instruments held by
Credit Suisse Group AG (indirectly via other Credit Suisse
entities) increased to 3.68%, as further explained below.
The Notification contains the following
information:
- Reason for the
Notification: Acquisition or disposal of voting securities
or voting rights.
- Notification by: A
parent undertaking or a controlling person.
- Person subject to the
notification requirement: Credit Suisse Group AG,
Paradeplatz 8, CH-8001 Zürich, Switzerland.
-
Transaction date: 28 January
2022.
- Threshold that is
crossed: 3%.
- Denominator: 57,545,663.
- Details of the
Notification: Credit Suisse Group AG now holds (indirectly
via other Credit Suisse entities) in aggregate 1,276,367 voting
rights (i.e., 2.22% of the total number of Biocartis shares as
compared to 3.08% notified to Biocartis on 11 October 2021) and
839,165 shares which it has out on loan to third parties with a
right to recall these at any time (i.e., 1.46% of total number of
Biocartis shares), resulting in an aggregate position of
3.68%.
- Full chain
of controlled undertakings through which the holding is effectively
being held: Credit Suisse Group AG,
Credit Suisse AG, Credit Suisse Asset Management International
Holding Ltd., Credit Suisse Asset Management & Investor Service
(Schweiz) Holding AG, Credit Suisse Fund Management S.A. / Credit
Suisse Group AG, Credit Suisse AG, Credit Suisse (Schweiz) AG /
Credit Suisse Group AG, Credit Suisse AG, Credit Suisse
International.
For further information, reference is made to
the Notification which is available here on the Biocartis
website.
Pursuant to the Belgian Transparency Act and the
articles of association of the Company, a notification to the
Company and the Belgian Financial Services and Markets Authority
(‘FSMA’) is required by all natural and legal persons in each case
where the percentage of voting rights in the Company held by such
persons reaches, exceeds or falls below the threshold of 3%, 5%,
10%, and every subsequent multiple of 5%, of the total number of
voting rights in the Company.
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail rdegrave@biocartis.com
tel
+32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer, as well as for
SARS-CoV-2/flu/RSV and sepsis. More
information: www.biocartis.com. Follow us on Twitter:
@Biocartis_. Biocartis and Idylla™ are registered trademarks in
Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Apr 2023 bis Apr 2024